Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.

Johnell, Olof LU ; Jönsson, Bengt ; Jönsson, Linus and Black, Dennis (2003) In PharmacoEconomics 21(5). p.305-314
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Postmenopausal: drug therapy, Postmenopausal: economics, Osteoporosis, Time Factors, Sweden, Postmenopausal: mortality, Quality of Life, Quality-Adjusted Life Years, Support, Non-U.S. Gov't, Age Factors, Aged, Alendronate: economics, Alendronate: therapeutic use, Cohort Studies, Cost-Benefit Analysis, Female, Fractures: economics, Fractures: prevention & control, Human, Markov Chains
in
PharmacoEconomics
volume
21
issue
5
pages
305 - 314
publisher
Adis International
external identifiers
  • wos:000182092500002
  • pmid:12627984
  • scopus:0037253242
ISSN
1179-2027
language
English
LU publication?
yes
id
00e59db2-b386-42ef-b142-cd0f5878f509 (old id 114334)
alternative location
http://www.ingentaconnect.com/content/adis/pec/2003/00000021/00000005/art00002
date added to LUP
2016-04-01 15:17:46
date last changed
2022-02-27 06:14:47
@article{00e59db2-b386-42ef-b142-cd0f5878f509,
  author       = {{Johnell, Olof and Jönsson, Bengt and Jönsson, Linus and Black, Dennis}},
  issn         = {{1179-2027}},
  keywords     = {{Postmenopausal: drug therapy; Postmenopausal: economics; Osteoporosis; Time Factors; Sweden; Postmenopausal: mortality; Quality of Life; Quality-Adjusted Life Years; Support; Non-U.S. Gov't; Age Factors; Aged; Alendronate: economics; Alendronate: therapeutic use; Cohort Studies; Cost-Benefit Analysis; Female; Fractures: economics; Fractures: prevention & control; Human; Markov Chains}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{305--314}},
  publisher    = {{Adis International}},
  series       = {{PharmacoEconomics}},
  title        = {{Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.}},
  url          = {{http://www.ingentaconnect.com/content/adis/pec/2003/00000021/00000005/art00002}},
  volume       = {{21}},
  year         = {{2003}},
}